T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

Cancer Discovery (Impact Factor: 19.45). 05/2014; 4(5):522-6. DOI: 10.1158/2159-8290.CD-13-0985
Source: PubMed


Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK-cell activation, and T/NK-cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic. Cancer Discov; 4(5); 522-6. ©2014 AACR.

Download full-text


Available from: Ana Rouzaut, Feb 01, 2016
  • Source
    • "Indeed, endothelial expression of the Endothelin B receptor has been shown to inhibit T-cell recruitment in ovarian cancer and decrease efficacy of cancer immunotherapy [12] . The location and quantity of tumorpromoting macrophages and tumor-inhibiting cytotoxic Tcells are predictive of survival in many types of solid tumors [13], and the success of cancer immunotherapy strictly depends on efficient recruitment of tumor-targeting immune cells [14]. Therefore, the endothelial barrier represents an attractive target for treatment of cancer [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Endothelial dysfunction plays a role in several processes that contribute to cancer-associated mortality. The vessel wall serves as a barrier for metastatic tumor cells, and the integrity and activation status of the endothelium serves as an important defense mechanism against metastasis. In addition, leukocytes, such as cytotoxic T-cells, have to travel across the vessel wall to enter the tumor tissue where they contribute to killing of cancer cells. Tumor cells can alter the characteristics of the endothelium by recruitment of leukocytes such as neutrophils and macrophages, which further stimulate inflammation and promote tumorigenesis. Recent findings also suggest that leukocyte-mediated effects on vascular function are not limited to the primary tumor or tissues that represent metastatic sites. Peripheral organs, such as kidney and heart, also display impaired vascular function in tumor-bearing individuals, potentially contributing to organ failure. Here, we discuss how vascular function is altered in malignant tissue and distant organs in individuals with cancer and how leukocytes function as potent mediators of these tumor-induced effects.
    Full-text · Article · Dec 2015 · Mediators of Inflammation
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epithelial ovarian cancer (EOC) is one of the most mortal carcinomas in females. Immune systems can recognize EOCs; however, a defect of HLA class I ex-pression is known to be a major mechanism for escape from immune systems, resulting in poor prognosis. The purpose of this study is to find novel relations between immunological response and other clinical factors. We investigated expression of immunological components in 122 cases of EOC for which opera-tions were performed in the period from 2001 to 2011. We stained EOC specimens immunohistochemically using an anti-pan HLA class I monoclonal antibody (EMR 8-5) and CD3, CD4, CD8 antibodies, and we analyzed correla-tions with immunological parameters and clinical factors. In multivariate analy-sis used the Cox proportional hazards model, independent prognostic factors for overall survival in advanced EOC were low expression level of HLA class I (RR= 1.97, 95%CI=1.01-3.83; p=0.046) and loss of intraepithelial cytotoxic T lympho-cyte (CTL) infiltration (RR=2.11, 95%CI=1.06-4.20; p=0.033). Interestingly, almost all platinum-resistant cases showed a significantly low rate of intraepi-thelial CTL infiltration in the χ square test (positive vs negative: 9.0% vs 97.7%, p<0.001). A logistic regression model revealed that low CTL infiltration rate was an independent factor of platinum resistance in multivariate analysis (OR=3.77, 95%CI=1.08-13.12; p=0.037). Platinum-resistant EOC shows poor immunological responses. The immune escape system of EOC may be one of the mechanisms of platinum resistance.
    No preview · Article · Oct 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and pembrolizumab has started to deliver on the long awaited promise of cancer immunotherapy. Many new modalities of immunotherapies targeting cytotoxic T lymphocytes (CTLs) responses, such as adoptive cell therapies and vaccines, are in advanced clinical trials. In all these immunotherapies, migration of CTLs to the tumor site is a critical step for achieving therapeutic efficacy. However, inefficient infiltration of activated CTLs into established tumors is increasingly being recognized as one of the major hurdles limiting efficacy. Mechanisms that control migration of CTLs to tumors are poorly defined. In this review, the authors discuss the chemoattractants and their receptors that have been implicated in endogenous- or immunotherapy-induced CTL recruitment to tumors and the potential for targeting these pathways for therapeutic efficacy.
    Full-text · Article · Dec 2014 · Expert Review of Vaccines
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.